Chris Bunge
Hedge fund analyst, long/short equity

ATMI Inc: Restructuring Underway, The Best Is Yet To Come

On December 23, 2013, ATMI (NASDAQ:ATMI) confirmed my prior analysis that they would sell or monetize their fast growing LifeScience division.(see article here)The press release stated: "ATMI has agreed to sell its LifeScience unit to Pall Corp. (NYSE:PLL) in a deal worth $185M, after-tax proceeds will be $165M." The sale is part of ATMI's ongoing exploration of strategic alternatives. The assets of the LifeScience business include two Belgian sites and a shared facility in Minnesota.

In my prior analysis I used a year end 2014 target valuation of 220M for their LifeScience division, which would be worth about $7/sh. From the look of it, this deal was a good one for ATMI, The deal...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details